← Back to Screener
Terns Pharmaceuticals, Inc. Common Stock (TERN)
Price$52.95
Growth ScoreF
Momentum ScoreA
Favorite Metrics
Price vs S&P 500 (26W)541.28%
Price vs S&P 500 (4W)-7.06%
VGM Score45.87
Market Capitalization$6.12B
All Metrics
Book Value / Share (Quarterly)$8.96
P/TBV (Annual)0.87x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.73
Price vs S&P 500 (YTD)23.78%
EPS (TTM)$-1.03
10-Day Avg Trading Volume2.44M
EPS Excl Extra (TTM)$-1.03
EPS (Annual)$-1.12
ROI (Annual)-25.69%
Cash / Share (Quarterly)$9.07
ROA (Last FY)-24.41%
Revenue Growth TTM (YoY)-100.00%
EBITD / Share (TTM)$-1.18
ROE (5Y Avg)-34.50%
Cash Flow / Share (Annual)$-0.73
P/B Ratio6.08x
P/B Ratio (Quarterly)4.27x
Net Income / Employee (Annual)$-1,506,000
ROA (TTM)-19.37%
EPS Incl Extra (Annual)$-1.12
Current Ratio (Annual)62.41x
Quick Ratio (Quarterly)62.09x
3-Month Avg Trading Volume4.52M
52-Week Price Return1412.86%
Tangible BV / Share (Quarterly)$4.18
P/S Ratio (Annual)6116.85x
Asset Turnover (Annual)0.01x
52-Week High$53.19
EPS Excl Extra (Annual)$-1.12
CapEx CAGR (5Y)-45.82%
26-Week Price Return548.90%
Quick Ratio (Annual)62.09x
13-Week Price Return46.84%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)62.41x
Enterprise Value$5.59B
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-4965.00%
Cash / Share (Annual)$9.07
3-Month Return Std Dev33.78%
Net Income / Employee (TTM)$-1,630,600
ROE (Last FY)-25.69%
EPS Basic Excl Extra (Annual)$-1.12
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.03
ROI (TTM)-20.02%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$5.16
Price vs S&P 500 (52W)1386.17%
Year-to-Date Return31.06%
5-Day Price Return0.04%
EPS Normalized (Annual)$-1.12
ROA (5Y Avg)-30.45%
Net Profit Margin (Annual)-5016.00%
Month-to-Date Return0.04%
Cash Flow / Share (TTM)$-1.27
EBITD / Share (Annual)$-1.28
Operating Margin (Annual)-4986.00%
ROI (5Y Avg)-32.65%
EPS Basic Excl Extra (TTM)$-1.03
P/TBV (Quarterly)0.94x
P/B Ratio (Annual)4.27x
Book Value / Share (Annual)$8.96
Price vs S&P 500 (13W)40.22%
Beta-0.21x
ROE (TTM)-20.02%
52-Week Low$3.06
gGradeF
mGradeA
vgmGradeC
Show chart for
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.24
4.28
3.82
3.47
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
TERNTerns Pharmaceuticals, Inc. Common Stock | — | F | A | $52.95 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing small-molecule therapies for non-alcoholic steatohepatitis (NASH) and other chronic liver diseases. The company's pipeline includes multiple candidates, including TERN-701, TERN-601, TERN-501, and TERN-800, designed for both single-agent and combination therapy approaches to address significant unmet clinical needs in liver disease treatment.